Dimension Therapeutics Inc (NASDAQ:DMTX) has earned an average rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $4.60.
Separately, Chardan Capital restated a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, December 22nd.
Dimension Therapeutics (NASDAQ:DMTX) traded down $0.03 during midday trading on Friday, reaching $5.95. The company’s stock had a trading volume of 27,700 shares, compared to its average volume of 150,214. The company has a market cap of $149.06 and a PE ratio of -2.67. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 3.33. Dimension Therapeutics has a 12-month low of $1.05 and a 12-month high of $6.10.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.